Bracco Suisse Sa

Bracco International Bv

Other

Hong (Helen) Fan

Rolf E Swenson

Philippe Bussat

Palaniappa Nanjappan

Radhakrishna K Pillai

Bo Song

Sibylle Pochon

Samir Cherkaoui

Bernard Lamy

Kondareddiar Ramalingam

Feng Yan

Adrian D Nunn

Karen E Linder

Michael F Tweedle

Edmund R Marinelli

Ramachandran S Ranganathan

Mathew A Von Wronski

Ajay Shrivastava

Christophe Arbogast

Sudha Khurana

The present invention provides polypeptides, peptide dimers, and multimeric complexes comprising at least one binding moiety for KDR or VEGF/KDR complex, which have a variety of uses wherever treating, detecting, isolating or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a K&#x3c;1 &#x3bc;M), and dimer and multimeric constructs comprising these polypeptides, particularly contrast agents. Also provided are methods for monitoring and evaluating the therapeutic effectiveness of treatment protocols for diseases associated with angiogenesis or endothelial cell hyperproliferation, such as cancer, using contrast agents of the invention.

KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Peptide vectors having high KDR binding affinity and processes for making such vectors are provided. The peptide vectors may be conjugated to phospholipids and included in ultrasound contrast agent compositions. Such ultrasound contrast agents are particularly useful in therapeutic and diagnostic methods, such as in imaging KDR-containing tissue and in the evaluation and treatment of angiogenic processes associated with neoplastic conditions. The present invention also provides processes for the large scale production of highly pure dimeric and monomeric peptide phospholipid conjugates as well as precursor materials used to form the conjugates. The present invention further provides processes for the large scale production of highly pure peptide phospholipid conjugates which contain very low levels of TFA.

Targeting vector-phospholipid conjugates

The invention provides radiopharmaceuticals for diagnostic and therapeutic applications, conjugates of antioxidants with metal chelating ligands, intermediate compounds, methods of making such radiopharmaceuticals, ligands, and intermediate compounds, and kits for preparing the radiopharmaceutical complexes.

Conjugates of antioxidants with metal chelating ligands for use in diagnostic and therapeutic applications

Growing community of inventors

Shanghai, China

Hong (Helen) Fan